Citation | Trial name | Intervention |
Zhang Y, et al[1] | Stockholm Tam | Tamoxifen for 2 versus 5 years versus nothing (tamoxifen 2 and 5 years combined in analysis) |
Sgroi DC, et al[2] | MA17 | Tamoxifen for 5 years, then letrozole versus placebo (extended; case control) |
Sgroi DC, et al[3] | ATAC | Tamoxifen versus anastrozole versus combined (combined not included in analysis) |
Sestak I, et al[4] | ATAC | |
Bartlett JM, et al[5] | aTTom | Tamoxifen at least 4 years, then tamoxifen versus nothing (extended; only the node positive) |
Bartlett JM, et al[6] | aTTom | |
Sgroi DC, et al[7] | aTTom | |
Noordhoek I, et al[8] | IDEAL | Tamoxifen or tamoxifen-aromatase inhibitor or aromatase inhibitor for 5 years, then 2.5 versus 5 years of letrozole (extended) |
Mamounas EP, et al[9] | B-42 | Endocrine therapy for 5 years, then letrozole versus placebo (extended) |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟